Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site induration, Vaccination site swelling, Vaccination site warmth
Clinical narrative: Hot to touch; Lump underneath the red splotch; red rash / Bright Red splotch 3 inch below the injection site; Hypersensitivity reaction; It is swollen; Pyrexia; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Hot to touch), VACCINATION SITE INDURATION (Lump underneath the red splotch), VACCINATION SITE ERYTHEMA (red rash / Bright Red splotch 3 inch below the injection site), HYPERSENSITIVITY (Hypersensitivity reaction) and VACCINATION SITE SWELLING (It is swollen) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 067F21A, 031A21A and 001C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Previously administered products included for Product used for unknown indication: Influenza (Manufacturer- Walgreens and Route-shot  Body site- Left) on 23-Oct-2021. Past adverse reactions to the above products included No adverse event with Influenza. Concomitant products included PROPRANOLOL (PROPANOLOL [PROPRANOLOL]) for Anxiety, ETHINYLESTRADIOL, LEVONORGESTREL (CHATEAL) for Birth control, OMEPRAZOLE for Reflux gastritis, LEVOTHYROXINE for Thyroid disorder, LIOTHYRONINE SODIUM (CYTOMEL) for Thyroid disorder NOS.   On 22-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 13-Nov-2021, the patient experienced VACCINATION SITE WARMTH (Hot to touch), VACCINATION SITE INDURATION (Lump underneath the red splotch), VACCINATION SITE ERYTHEMA (red rash / Bright Red splotch 3 inch below the injection site), HYPERSENSITIVITY (Hypersensitivity reaction), VACCINATION SITE SWELLING (It is swollen) and PYREXIA (Pyrexia). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) (topical) from 13-Nov-2021 to 15-Nov-2021 for Adverse event, at a dose of 1 UNK and CORTISONE (topical) from 13-Nov-2021 to 15-Nov-2021 at a dose of UNK dosage form. On 15-Nov-2021, VACCINATION SITE WARMTH (Hot to touch), VACCINATION SITE INDURATION (Lump underneath the red splotch), VACCINATION SITE ERYTHEMA (red rash / Bright Red splotch 3 inch below the injection site), HYPERSENSITIVITY (Hypersensitivity reaction), VACCINATION SITE SWELLING (It is swollen) and PYREXIA (Pyrexia) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 13-Nov-2021, Body temperature: 99.5 (High) 99.5 F. On 13-Nov-2021, Heart rate: abnormal (abnormal) more than 100 beats per min. On 14-Nov-2021, Body temperature: 99.5 (High) 99.5 F. On 15-Nov-2021, Body temperature: 98.7 (normal) 98.7 F.         Patient had symptoms includes Itching Local, Redness Local,Chills,Redness Local.   This case was linked to MOD-2021-385818 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 15-Nov-2021: Patient demographics, Medical history, Lab data, Route of administration of concomitant medication, Treatment drug and new events were added.